RxDoctor Payments Data

Carlos Calle-Muller

Clinical Cardiac Electrophysiology · Cumming, GANPI 1891081576

Payments from drug & device makers

$13,261in general payments, 2019–2025

Across 319 payments — averaging $41.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$3K
  • Boston Scientific$2K
  • Pfizer$539
  • Atricure, Inc.$440
  • Novartis$415
  • plus $3K from 31 others

What the payments were for

  • Travel & lodging$1,1849%
  • Food & beverage$12,06491%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,261 in reported general payments places this provider in the 30th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

See all clinical cardiac electrophysiology providers in Georgia

Medicare billing

Part B allowed, 2024
$1,035,082
Medicare patients
1,498
Services billed
10,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban752$832,239
XareltoRivaroxaban210$248,489
EntrestoSacubitril/Valsartan24$39,038
Dabigatran EtexilateDabigatran Etexilate Mesylate25$7,632
SotalolSotalol Hcl427$6,453
Metoprolol Succinate395$5,328
Flecainide Acetate116$4,228
Potassium Chloride157$4,094
Diltiazem 12hr ErDiltiazem Hcl19$2,399
Diltiazem 24hr Er (Cd)Diltiazem Hcl73$2,263
Amiodarone Hcl102$1,795
Propafenone Hcl ErPropafenone Hcl12$1,720
Losartan Potassium213$1,531
Nifedipine ErNifedipine20$1,421
Carvedilol185$1,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$539$832,239752 claims
Johnson & JohnsonXarelto$236$248,489210 claims
NovartisEntresto$415$39,03824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

Other clinical cardiac electrophysiology in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →